Drug Trial Radar · NCT05156281
Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS)
Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
1,007
Actual
Start
Dec 13, 2021
Primary completion
Jul 22, 2026
Study completion Oct 30, 2030
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Dec 14, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To compare the efficacy and safety of remibrutinib versus teriflunomide in patients with relapsing multiple sclerosis (RMS)
Conditions
- Relapsing Multiple Sclerosis
Interventions
RemibrutinibDrug
tablet taken orally
TeriflunomideDrug
capsule taken orally
Primary outcomes
What the sponsor says the trial is designed to measure.
- Annualized relapse rate (ARR) of confirmed relapses [Core Part]Time frame: From Baseline, up to 30 months
Locations
223 sites in 27 countries. Site status is shown where the registry gives one.
Ctr for Neurology and Spine
Phoenix, Arizona
Vladimir Royter MD APMC
Hanford, California
VA Greater LA Healthcare System
Los Angeles, California
Regina Berkovich MD PhD Inc
West Hollywood, California
CU Anschutz Med Campus
Aurora, Colorado
Colorado Neurological Research PC
Denver, Colorado
New England Institute for Clinical Research
Stamford, Connecticut
Georgetown University Hospital Research
Washington D.C., District of Columbia
Georgetown University Hospital
Washington D.C., District of Columbia
Nova Clinical Research LLC
Bradenton, Florida
University of Florida
Gainesville, Florida
Memorial Healthcare System
Hollywood, Florida
Neurology Associates PA
Maitland, Florida
Gables Neurology
Miami, Florida
UM Department Of Neurology
Miami, Florida
Aqualane Clinical Research
Naples, Florida
Advent Health Orlando
Orlando, Florida
Humanity Clinical Research
Pembroke Pines, Florida
Emerald Coast Neurology
Pensacola, Florida
Brain and Spine Institute
Port Orange, Florida
Vero Beach Neurology
Vero Beach, Florida
Conquest Research
Winter Park, Florida
Methodist Neuroscience Institute
Merrillville, Indiana
University of Kansas Hospital
Kansas City, Kansas
Baptist Physicians Lexington
Nicholasville, Kentucky
Ochsner Clinic Foundation
New Orleans, Louisiana
Clinre Comprehensive Neurology
Frederick, Maryland
Tufts Medical Center
Boston, Massachusetts
Kansas City VA Medical Center
Kansas City, Missouri
South Shore Neurologic Associates
Patchogue, New York
University Of NC At Chapel Hill
Chapel Hill, North Carolina
Piedmont HealthCare
Charlotte, North Carolina
The Boster Ctr for MS
Columbus, Ohio
Neurology Diagnostics Inc
Dayton, Ohio
Penn State Hershey Medical Center
Hershey, Pennsylvania
Premier Neurology
Greenville, South Carolina
Metrolina Neurological Associates PA
Old Point Station, South Carolina
Sibyl Wray MD Neurology PC
Knoxville, Tennessee
Carum Research
Dallas, Texas
Med Research Inc
El Paso, Texas
Showing 40 of 223 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.